Cargando…

Pulmonary Hypertension Secondary to COPD

The development of pulmonary hypertension in COPD adversely affects survival and exercise capacity and is associated with an increased risk of severe acute exacerbations. Unfortunately not all patients with COPD who meet criteria for long term oxygen therapy benefit from it. Even in those who benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shujaat, Adil, Bajwa, Abubakr A., Cury, James D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437672/
https://www.ncbi.nlm.nih.gov/pubmed/22973510
http://dx.doi.org/10.1155/2012/203952
_version_ 1782242815139381248
author Shujaat, Adil
Bajwa, Abubakr A.
Cury, James D.
author_facet Shujaat, Adil
Bajwa, Abubakr A.
Cury, James D.
author_sort Shujaat, Adil
collection PubMed
description The development of pulmonary hypertension in COPD adversely affects survival and exercise capacity and is associated with an increased risk of severe acute exacerbations. Unfortunately not all patients with COPD who meet criteria for long term oxygen therapy benefit from it. Even in those who benefit from long term oxygen therapy, such therapy may reverse the elevated pulmonary artery pressure but cannot normalize it. Moreover, the recent discovery of the key roles of endothelial dysfunction and inflammation in the pathogenesis of PH provides the rationale for considering specific pulmonary vasodilators that also possess antiproliferative properties and statins.
format Online
Article
Text
id pubmed-3437672
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34376722012-09-12 Pulmonary Hypertension Secondary to COPD Shujaat, Adil Bajwa, Abubakr A. Cury, James D. Pulm Med Review Article The development of pulmonary hypertension in COPD adversely affects survival and exercise capacity and is associated with an increased risk of severe acute exacerbations. Unfortunately not all patients with COPD who meet criteria for long term oxygen therapy benefit from it. Even in those who benefit from long term oxygen therapy, such therapy may reverse the elevated pulmonary artery pressure but cannot normalize it. Moreover, the recent discovery of the key roles of endothelial dysfunction and inflammation in the pathogenesis of PH provides the rationale for considering specific pulmonary vasodilators that also possess antiproliferative properties and statins. Hindawi Publishing Corporation 2012 2012-08-29 /pmc/articles/PMC3437672/ /pubmed/22973510 http://dx.doi.org/10.1155/2012/203952 Text en Copyright © 2012 Adil Shujaat et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Shujaat, Adil
Bajwa, Abubakr A.
Cury, James D.
Pulmonary Hypertension Secondary to COPD
title Pulmonary Hypertension Secondary to COPD
title_full Pulmonary Hypertension Secondary to COPD
title_fullStr Pulmonary Hypertension Secondary to COPD
title_full_unstemmed Pulmonary Hypertension Secondary to COPD
title_short Pulmonary Hypertension Secondary to COPD
title_sort pulmonary hypertension secondary to copd
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437672/
https://www.ncbi.nlm.nih.gov/pubmed/22973510
http://dx.doi.org/10.1155/2012/203952
work_keys_str_mv AT shujaatadil pulmonaryhypertensionsecondarytocopd
AT bajwaabubakra pulmonaryhypertensionsecondarytocopd
AT curyjamesd pulmonaryhypertensionsecondarytocopd